Flexible Low-Dose GnRH Antagonist Protocol Is Effective in Patients With Sufficient Ovarian Reserve in IVF
Open Access
- 19 December 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 9, 767
Abstract
Gonadotropin-releasing hormone antagonist (GnRH-ant) has been shown to negatively influence endometrial receptivity. Reducing the GnRH-ant dose during controlled ovarian stimulation (COS) when using a GnRH-ant protocol may be beneficial to embryo implantation. However, whether or not the minimum daily GnRH-ant dose should be individualized remains uncertain. In this retrospective study, we aimed to elucidate the feasibility and effectiveness of moderately reducing the daily GnRH-ant dose to 0.125 mg, and then adjusting the dose to 0.25 mg based on subsequent luteinizing hormone (LH) levels. Of the 434 patients analyzed in this study, 209 received our new flexible low-dose GnRH-ant protocol (Group 1) and 225 received a conventional GnRH-ant protocol with a fixed daily dose of 0.25 mg (Group 2). Furthermore, 105 and 114 cycles from groups 1 and 2 received fresh embryo transfer. In Group 1, 30 patients whose dose of 0.125 mg GnRH-ant was adjusted according to their LH levels and 179 patients who received consistently low doses were further divided into subgroups 1 and 2, respectively. Neither the number of retrieved oocytes and available embryos nor the implantation rate, clinical pregnancy rate, and ongoing pregnancy rate significantly differed between the two groups. However, GnRH-ant dose and stimulation duration were much lower and shorter in Group 1 than in Group 2 (P < 0.05). Subgroup 1 exhibited higher basal follicle-stimulating hormone (FSH) and lower antral follicle count (AFC) than subgroup 2 significantly. The number of retrieved oocytes and available embryos were lower in subgroup 1 than in subgroup 2 (6.83 ± 3.28 vs. 11.83 ± 4.82, 2.93 ± 1.86 vs. 4.99 ± 3.46, respectively, p < 0.05), while more cancelled cycles for pre-ovulation occurred in subgroup 1 than in subgroup 2 (3/30 vs. 1/179, p < 0.05). The results showed that the flexible low-dose GnRH-ant protocol was as effective as the conventional fixed-dose GnRH-ant protocol with 0.25 mg per day for most patients with normal ovarian reserve. This retrospective analysis and the small sample size are the main limitations of this study, and a large sample RCT trail will be carried out in future.Keywords
Funding Information
- Shanghai Municipal Education Commission (20181803)
- Chinese Medical Association (16020480664)
- Shanghai Jiao Tong University (YG2017ZD11, YG2017MS57)
- National Natural Science Foundation of China (81501249)
This publication has 34 references indexed in Scilit:
- Optimal usage of the GnRH antagonists: a review of the literatureReproductive Biology and Endocrinology, 2013
- The effect of human cumulus cells on the maturation and developmental potential of immature oocytes in ICSI cyclesJournal of Assisted Reproduction and Genetics, 2012
- Ovarian Reserve Assessment for Infertility InvestigationISRN Obstetrics and Gynecology, 2012
- Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trialFertility and Sterility, 2011
- Assisted reproductive treatment outcome in a large cohort of women with serum FSH above 15 IU/LFertility and Sterility, 2009
- Antral follicle count is a significant predictor of livebirth in in vitro fertilization cyclesFertility and Sterility, 2009
- Comparisons of Different Dosages of Gonadotropin-Releasing Hormone (GnRH) Antagonist, Short-acting Form and Single, Half-dose, Long-acting Form of GnRH Agonist During Controlled Ovarian Hyperstimulation and in vitro FertilizationTaiwanese Journal of Obstetrics and Gynecology, 2008
- Preliminary Report on the Effect of a Lower Dose of Gonadotropin-Releasing Hormone Antagonist (Cetrorelix) on Ovarian Hyperstimulation in Lower-Weight Asian WomenTaiwanese Journal of Obstetrics and Gynecology, 2006
- Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?Journal of Assisted Reproduction and Genetics, 2006
- Gonadotrophin-releasing hormone antagonists for assisted conception2001